ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $401,220.00 in Stock

Key Points

• ANI Pharmaceuticals CEO Nikhil Lalwani sold 5,400 shares at an average price of $74.30, generating $401,220. The Rule 10b5-1 transaction reduced his direct stake by 1.54% to 344,489 shares.
• ANIP shares fell $1.09 to $74.56, near the lower end of their 52-week range of $70.15 to $99.50. The company has a $1.71 billion market capitalization and trades at a price-to-earnings ratio of 16.07.
• ANI Pharmaceuticals recently exceeded quarterly earnings and revenue estimates, reporting $2.21 in EPS and $266.04 million in revenue, with revenue up 25.8% year over year. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $105.83.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CEO Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total transaction of $401,220.00. Following the completion of the sale, the chief executive officer directly owned 344,489 shares in the company, valued at approximately $25,595,532.70. This represents a 1.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock traded down $1.09 during trading hours on Wednesday, hitting $74.56. 411,903 shares of the company were exchanged, compared to its average volume of 380,614. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of 16.07 and a beta of 0.44. The firm has a fifty day simple moving average of $80.05 and a 200 day simple moving average of $78.80. ANI Pharmaceuticals, Inc. has a 52-week low of $70.15 and a 52-week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same period in the prior year, the company earned $1.80 earnings per share. ANI Pharmaceuticals's revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. Amundi increased its stake in ANI Pharmaceuticals by 595.5% in the 2nd quarter. Amundi now owns 31,793 shares of the specialty pharmaceutical company's stock worth $2,632,000 after acquiring an additional 27,222 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of ANI Pharmaceuticals during the second quarter worth about $1,449,000. California State Teachers Retirement System increased its position in shares of ANI Pharmaceuticals by 7,977.4% in the second quarter. California State Teachers Retirement System now owns 1,983,574 shares of the specialty pharmaceutical company's stock worth $164,200,000 after purchasing an additional 1,959,017 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $724,000. Finally, Penn Capital Management Company LLC raised its stake in ANI Pharmaceuticals by 15.4% in the second quarter. Penn Capital Management Company LLC now owns 207,362 shares of the specialty pharmaceutical company's stock valued at $17,183,000 after purchasing an additional 27,646 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ANIP shares. Zacks Research downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 14th. Canaccord Genuity Group cut their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a report on Monday, August 10th. Guggenheim reduced their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a research note on Monday, August 10th. Weiss Ratings cut shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Finally, Wall Street Zen lowered ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 8th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $105.83.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source